Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Stellar Biotechnologies Files Provisional Application for Patent for KLH Adjuvant Innovations

PORT HUENEME, CA -- (Marketwire) -- 02/06/13 -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company has submitted a provisional application for a patent to the U.S. Patent and Trademark Office for new innovations related to Stellar's Keyhole Limpet Hemocyanin ("KLH")-based combinatorial adjuvant technology. The application included claims for pharmaceutical grade adjuvant compositions, manufacturing processes and uses in a wide range of vaccine therapies.

A fast-growing, leading sector of pharmaceutical development is the area of therapeutic vaccines -- vaccines that mobilize the immune system to fight cancer, autoimmune conditions, infectious diseases and viruses. However, many therapeutic vaccines require an adjuvant to be effective. Stellar's KLH-based adjuvant platform has the potential to improve vaccine potency, reduce toxicities and offer highly targeted immune activation.

"One of the biggest challenges in developing therapeutic vaccines has been the need for safe, robust adjuvants," said Stellar CTO, Herbert Chow, Ph.D. "Stellar Biotechnologies has developed a new combinatorial adjuvant technology based on the long-standing safety and well-recognized immune-stimulating properties of KLH."

Stellar President and CEO Frank Oakes said, "Vaccine adjuvants have multi-billion market potential. We believe Stellar's KLH-based approach, and new intellectual property, positions us to enter this industry field, and will be valuable to major pharmaceutical partners."

KLH is a naturally derived protein typically used as a carrier protein in therapeutic vaccines or a stimulant in immunotoxicology applications.

For more information:

Discovery Medicine on Adjuvants and scroll down to "Why Do We Need Adjuvants?"

http://bit.ly/11fVSOL

Stellar's Website -- www.StellarBiotech.com and the KLH Information Site -- www.KLHSite.com

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/

Forward-Looking Statements

The Company's views as of the date of this press release should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contacts:

Stellar Biotechnologies, Inc.
Darrell Brookstein
Executive VP, Corporate Development and Finance
Phone: 805 488 2800
Email: dbrookstein@stellarbiotech.com

Investor Relations:
MZ Group
Mark A. McPartland
Senior Vice President
Phone: 1 212-301-7130
Email: markmcp@mzgroup.us
Web: www.mzgroup.us

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Cloud Developer Stories
Avaya has escalated its efforts to get customers to fast-track to the cloud with the first of several sweeping initiatives that will optimize solutions and processes for delivery of collaboration as a service (CaaS) via the Avaya Collaborative Cloud. Strong demand for Avaya commu...
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a ...
This independent report from Info-Tech evaluates and scores 14 companies in the Virtual Machine Backup market. It can help you understand what's new in the virtual backup market, evaluate virtual backup vendors and products for your needs and determine which products are most app...
CodeFutures, a provider of agile Big Data technologies, on Tuesday announced the release of Cory Isaacson’s newest book, “Understanding Big Data Scalability.” Isaacson is the CEO/CTO for CodeFutures and an industry-leading innovator of data management software. “Understanding Big...
Cloud Computing is evolving into a Big Three of Amazon Web Services, Google Cloud, and Microsoft Azure. Cloud 360: Multi-Cloud Bootcamp, being held Nov 4–5, 2014, in conjunction with 15th Cloud Expo in Santa Clara, CA, delivers a real-world demonstration of how to deploy and co...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News

Rovi Corporation (NASDAQ:ROVI), a global leader in entertainment discovery, today a...